GlassScriptPhysician profile
Jennifer L Conley
NPI 1194720862
$1,319.39
in general payments reported to CMS, 2019-2025
27 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2023: $170 · 2024: $189 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $653.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $280.77 | 2019-2024 | Breztri, Farxiga |
| Amgen INC. | $144.29 | 2019 | |
| Medline Industries LP | $103.12 | 2023-2025 | |
| Abbvie INC. | $84.37 | 2023-2025 | Qulipta, Vraylar, Dalvance |
| Axsome Therapeutics, INC. | $74.08 | 2025 | Auvelity |
| Glaxosmithkline, LLC. | $61.11 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $60.89 | 2019-2024 | |
| Organon LLC | $50.80 | 2023-2024 | Nexplanon |
| Avanir Pharmaceuticals, INC. | $47.92 | 2019 | |
| Novo Nordisk INC | $46.57 | 2019 | |
| Janssen Pharmaceuticals, INC | $35.51 | 2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.72 | 2019-2024 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $30.44 | 2025 | Uzedy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.02 | 2019 | |
| Lundbeck LLC | $27.78 | 2025 | Rexulti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $27.47 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $22.94 | 2025 | Rexulti |
| Astellas Pharma US INC | $21.93 | 2025 | Veozah |
| Sanofi Pasteur INC. | $21.43 | 2025 | |
| Exeltis, USA INC. | $20.83 | 2024 | Slynd |
| Hologic Sales and Service, LLC | $19.39 | 2024 | Thinprep 2000 Processor, Aptima |
| Merck Sharp & Dohme LLC | $15.13 | 2019 | |
| Radius Health, INC. | $14.36 | 2019 | |
| Sage Therapeutics, LLC | $13.52 | 2019 | |
| Lilly USA, LLC | $12.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.66 | 2019 | |
| Mylan Specialty L.P. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Conley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.